Allurion Technologies, Inc. - ALUR STOCK NEWS

Allurion Technologies (NYSE: ALUR) has launched AllurionMeds, combining compounded GLP-1 medications with an AI-powered platform featuring Coach Iris for weight management. The program includes virtual dietician access and a smart scale measuring weight, muscle, and bone mass. The initiative addresses key GLP-1 challenges: medication adherence, muscle mass loss, and high costs. The program utilizes FDA-registered pharmacies for drug sourcing and expands Allurion's presence to all 50 US states. This launch targets a projected $100 billion GLP-1 market expected to reach 30 million users by 2030.

Allurion Technologies (NYSE: ALUR) reported Q3 2024 financial results with revenue of $5.4 million, down from $18.2 million in Q3 2023. The decline was attributed to destocking, macroeconomic headwinds, and suspended sales in France. The company's AI Virtual Care Suite revenue grew 82% year-over-year. Gross profit margin decreased to 58% from 77% in Q3 2023. The company updated its full-year 2024 revenue guidance to $30-35 million and announced a restructuring plan targeting 50% reduction in operating expenses, aiming for profitability by end of 2025.

Allurion Technologies (NYSE: ALUR) presented significant data at Obesity Week 2024, showcasing results from their largest real-world study involving 19,428 patients across 72 countries. The study demonstrated an average weight reduction of 12.2% after four months using the Allurion Program. Additionally, a second study revealed that patients who previously had unsuccessful results with liraglutide achieved an average 17.6% weight reduction after four months on the Allurion Program. This group included patients where 55% had no weight loss and 45% had less than 5% weight loss with GLP-1 medications.

Allurion Technologies (NYSE: ALUR) has announced it will report its third quarter 2024 financial results on November 13, 2024. The company will host a conference call at 8:30 AM ET on the same day to discuss financial results and provide a business update. Investors can access the call via telephone at (888) 330-3417 (domestic) or +1 646 960 0804 (international) using Conference ID 1905455. A live audio webcast will be available on Allurion's Investor Relations website, with replay options available afterward.

Allurion Technologies (NYSE: ALUR) has submitted the first three modules of its premarket approval application (PMA) to the FDA for the Allurion Balloon, with the fourth and final module containing clinical data from the AUDACITY trial expected early next year. The Allurion Balloon is the world's first swallowable, procedureless gastric balloon for weight loss that requires no surgery, endoscopy, or anesthesia. The device can be placed in 15 minutes during an outpatient visit and naturally passes from the body after four months. Over 150,000 patients have been treated with the balloon outside the US. The AUDACITY trial, involving 550 patients across 17 US sites, completed enrollment ahead of schedule and is expected to conclude by end of 2024.

Allurion Technologies (NYSE: ALUR) has published a study in Clinical Obesity showcasing the effectiveness of the Allurion Program for weight loss and body composition improvement. The study, involving 167 patients with an average BMI of 31.3, demonstrated:

- 15.7% average weight reduction at 4 months
- 17.1% average weight loss at 6 months
- 14.7% average weight loss maintained at 12 months

Notably, patients experienced a significant decrease in body fat percentage from 39% to 35.7% at 6 months, while preserving muscle mass. The study reported no serious adverse events, highlighting the safety and efficacy of the Allurion Balloon in achieving sustainable weight loss and improved body composition.

Allurion Technologies (NYSE: ALUR) has announced the publication of a meta-analysis demonstrating the safety and effectiveness of the Allurion Program for weight loss. The systematic review, which analyzed 11 studies involving 2,107 patients conducted between 2016 and 2024, reported an average weight reduction of 12.5% and a significant BMI reduction of 4.75 kg/m2 at four months.

The analysis also confirmed the safety of the Allurion Balloon, with a low rate of serious adverse events at just 0.90%. Additionally, the study highlighted improvements in metabolic health parameters, including HDL cholesterol, triglycerides, and glycemia. Dr. Ram Chuttani, Chief Medical Officer and Founding Partner of Allurion, emphasized that these results further support the established safety and effectiveness of the Allurion Balloon, which has been documented in 26 peer-reviewed journal articles and used to treat over 150,000 patients worldwide.

Allurion Technologies (NYSE: ALUR), a company focused on ending obesity, has received a continued listing standards notice from the New York Stock Exchange (NYSE). The notice indicates that Allurion is not in compliance with NYSE's listing standards due to its average market capitalization falling below $50 million over a 30-day trading period ending August 29, 2024, and its last reported stockholders' equity being less than $50 million.

Allurion has 45 days to submit a plan to the NYSE outlining actions to regain compliance. If accepted, the company will have an 18-month cure period to meet the standards, during which its stock will continue to trade on the NYSE, subject to compliance with other listing requirements and periodic reviews.

Allurion Technologies (NYSE: ALUR) has published a study on the safety and effectiveness of the Allurion Program in adolescents with obesity. The study involved 91 adolescents aged 15-17 with an average BMI of 35.6. Key findings include:

- Average weight reduction of 13.1% four months after balloon placement
- No serious adverse events or early device removals
- Allurion Balloon offers a non-invasive treatment option for adolescent obesity

The study addresses growing concerns about adolescent obesity, which has quadrupled worldwide since 1990. The Allurion Balloon presents an alternative to invasive bariatric surgery and long-term pharmacotherapy, which raise concerns when applied to adolescents.